The Journal of Steroid Biochemistry and Molecular Biology ( IF 4.1 ) Pub Date : 2020-06-11 , DOI: 10.1016/j.jsbmb.2020.105719 Jose Manuel Quesada-Gomez 1 , Marta Entrenas-Castillo 2 , Roger Bouillon 3
Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months.
中文翻译:
维生素D受体刺激可减少冠状病毒SARS-CoV-2感染患者的急性呼吸窘迫综合征(ARDS):SBMB女士2020_166修订版。
冠状病毒感染是严重的健康问题,需要有效的疫苗和/或抗病毒治疗。冠状病毒病2019(COVID-19)的主要并发症是急性呼吸窘迫综合征(ARDS),归因于多种机制,包括细胞因子风暴,肾素-血管紧张素系统失调,中性粒细胞活化和(微)凝血增加。根据许多人类的临床前研究和观察数据,ARDS可能因维生素D缺乏而加剧,而由于维生素D受体的激活而逐渐降低。正在进行使用口服维生素D或口服Calcifediol(25OHD)的一些随机临床试验。根据一项初步研究,口服降钙素可能是最有前途的方法。这些研究有望在几个月内提供指导。